Literature DB >> 21878365

2,3-Diaryl-2H-1-benzopyran derivatives interfere with classical and non-classical estrogen receptor signaling pathways, inhibit Akt activation and induce apoptosis in human endometrial cancer cells.

I Fatima1, V Chandra, R Saxena, M Manohar, Y Sanghani, K Hajela, M P S Negi, P L Sankhwar, S K Jain, A Dwivedi.   

Abstract

OBJECTIVES: The present study was undertaken to explore the mechanism of anti-proliferative action of benzopyran compound D1 (2-[piperidinoethoxyphenyl]-3-phenyl-2H-benzopyran) and its hydroxy-(D2) and methoxy-(D3) derivatives in Ishikawa and human primary endometrial adenocarcinoma cells.
METHODS: Transcriptional activation assays were performed using luciferase reporter system and cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The stage of cell cycle was determined by flow-cytometry and real time analysis of cyclinE1 and cdc2 genes. The apoptotic effects were measured by AnnexinV/PI staining and TUNEL. The expression of PCNA, cyclinD1, pAkt, XIAP, cleaved caspase-9, -3, PARP, Bax and Bcl2 were determined by immunoblotting. The caspase-3 activity and mitochondrial membrane potential were measured by colorimetric assay.
RESULTS: All three compounds inhibited E(2)-induced ERE- and AP-1-mediated transactivation and proliferation in endometrial adenocarcinoma cells dose-dependently. Compound D1 caused the arrest of cells in the G(2) phase while D2 and D3 caused arrest in G(1) phase of the cell cycle. All compounds interfered with Akt activation, decreased XIAP expression leading to an increased cleavage of caspase-9, -3, PARP, increased Bax/Bcl2 ratio and caspase-3 activity.
CONCLUSION: Findings suggest that benzopyran derivatives inhibit cellular proliferation via modulating ER-dependent classical and non-classical signaling mechanisms, interfere with Akt activation and induce apoptosis via intrinsic pathway in endometrial adenocarcinoma cells.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21878365     DOI: 10.1016/j.mce.2011.08.018

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  7 in total

1.  Tandem Alkyne Hydroacylation and Oxo-Michael Addition: Diastereoselective Synthesis of 2,3-Disubstituted Chroman-4-ones and Fluorinated Derivatives.

Authors:  Xiang-Wei Du; Levi M Stanley
Journal:  Org Lett       Date:  2015-06-22       Impact factor: 6.005

2.  Effects of Raf kinase inhibitor protein expression on pancreatic cancer cell growth and motility: an in vivo and in vitro study.

Authors:  Haisu Dai; Haowei Chen; Wei Liu; Yu You; Jiaxin Tan; Aigang Yang; Xiangdong Lai; Ping Bie
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-21       Impact factor: 4.553

3.  Inhibitory effect of 2-(piperidinoethoxyphenyl)-3-(4-hydroxyphenyl)-2H-benzo(b)pyran (K-1) on human primary endometrial hyperplasial cells mediated via combined suppression of Wnt/β-catenin signaling and PI3K/Akt survival pathway.

Authors:  V Chandra; I Fatima; M Manohar; P Popli; V K Sirohi; M K Hussain; K Hajela; P Sankhwar; A Dwivedi
Journal:  Cell Death Dis       Date:  2014-08-21       Impact factor: 8.469

Review 4.  Therapeutic options for management of endometrial hyperplasia.

Authors:  Vishal Chandra; Jong Joo Kim; Doris Mangiaracina Benbrook; Anila Dwivedi; Rajani Rai
Journal:  J Gynecol Oncol       Date:  2015-12-01       Impact factor: 4.401

5.  Paeoniflorin inhibits proliferation of endometrial cancer cells via activating MAPK and NF-κB signaling pathways.

Authors:  Jianxin Zhang; Fengchun Wang; Huali Wang; Yanna Wang; Yan Wu; Hui Xu; Chen Su
Journal:  Exp Ther Med       Date:  2017-10-02       Impact factor: 2.447

Review 6.  Targeting Wnt Signaling in Endometrial Cancer.

Authors:  Iram Fatima; Susmita Barman; Rajani Rai; Kristina W W Thiel; Vishal Chandra
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

7.  Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways.

Authors:  Ruchi Saxena; Vishal Chandra; Murli Manohar; Kanchan Hajela; Utsab Debnath; Yenamandra S Prabhakar; Karan Singh Saini; Rituraj Konwar; Sandeep Kumar; Kaling Megu; Bal Gangadhar Roy; Anila Dwivedi
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.